International research networks in pediatric rheumatology: The PRINTO perspective

Current Opinion in Rheumatology

Volumn 16, Issue 5, 2004, Pages 566-570

  Ruperto, Nicolino ^a,b   Martini, Alberto ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b G GASLINI INSTITUTE   (Italy)

Author keywords

Clinical trials; Collaborative research; Pediatric rheumatic diseases; Quality of life

Indexed keywords

METHOTREXATE;

CHILD HEALTH; CLINICAL RESEARCH; CULTURAL FACTOR; DERMATOMYOSITIS; DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; EVALUATION; FOOD AND DRUG ADMINISTRATION; HEALTH PROMOTION; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MEDICAL ASSESSMENT; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REMISSION; REVIEW; STANDARDIZATION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; BIOMEDICAL RESEARCH; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; HUMANS; INTERNATIONAL COOPERATION; PEDIATRICS; QUALITY OF LIFE; RHEUMATIC DISEASES; RHEUMATOLOGY;

EID: 4344638042     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000130286.54383.ea     Document Type: Review

References (36)

1. Allaire SH, DeNardo BS, Szer IS, et al.: The economic impacts of juvenile rheumatoid arthritis. J Rheumatol 1992, 19:952-955.
2. Ruperto N, Levinson JE, Ravelli A, et al.: Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. I. Outcome status. J Rheumatol 1997, 24:945-951.
3. Ruperto N, Ravelli A, Levinson JE, et al.: Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. II. Early predictors of outcome. J Rheumatol 1997, 24:952-958.
4. Ravelli A, Duarte-Salazar C, Buratti S, et al.: Assessment of damage in juvenile-onset systemic lupus erythematosus. A multicenter cohort study. Arthritis Rheum 2003, 49:501-507. This is another example of a collaborative project that allows the recruitment of a large sample of pediatric patients impossible to be achieved in a single-center study.
5. Committee on Drugs, American Academy of Pediatrics: Guidelines for the ethical conduct of studies to evaluate drugs in a pediatric population. Pediatrics 1995, 95:286-294.
6. Committee on Bioethics: Informed consent, parental permission, and assent in pediatric practice. Pediatrics 1995, 95:286-294.
7. Rothman KJ, Michels KB: The continuing unethical use of placebo controls. N Engl J Med 1994, 331:394-398.
8. Schechter C: The use of placebo controls. N Engl J Med 1995, 332:60-61.
9. Taubes G: Medical research: use of placebo controls in clinical trials disputed. Science 1995, 267:25-26.
10. Reiff A, Shaham B, Wood BP, et al.: High dose methotrexate in the treatment of refractory juvenile rheumatoid arthritis. Clin Exp Rheumatol 1995, 13:113-118.
11. Wallace CA, Sherry DD: Preliminary report of higher dose methotrexate treatment in juvenile rheumatoid arthritis. J Rheumatol 1992, 19:1604-1607.
12. Miller LC, Sisson BA, Tucker LB, et al.: Methotrexate treatment of recalcitrant childhood dermatomyositis. Arthritis Rheum 1992, 35:1143-1149.
13. Lovell DJ, Giannini EH, Brewer EJ: Time course of response to nonsteroidal antiinflammatory drugs in juvenile rheumatoid arthritis. Arthritis Rheum 1984, 27:1433-1437.
14. Brewer EJ, Giannini EH: Methodology and studies of children with juvenile rheumatoid arthritis. J Rheumatol 1982, 9:107-139.
15. Brewer EJ, Giannini EH: Standard methodology for segment I, II, and III pediatric rheumatology collaborative study group studies. I. Design. J Rheumatol. 1982, 9:109-113. This is a reference paper with the methodology to conduct collaborative studies in JRA
16. Giannini EH, Brewer EJ: Standard methodology for segment I, II, and III pediatric rheumatology collaborative study group studies. II. Analysis and presentation of data. J Rheumatol 1982, 9:114-122.
17. Giannini EH: The N of 1 trials design in the rheumatic diseases. Arthritis Care Res 1988, 1:109-115.
18. Giannini EH, Shaikov A, Maximov A, et al.: Meta-analysis of antirheumatic drug trials in juvenile rheumatoid arthritis. Arthritis Rheum 1991, 34:s152.
19. Giannini EH, Brewer EJ, Person DA: Auranofin in the treatment of juvenile rheumatoid arthritis. J Pediatr 1983, 102:138-141.
20. Brewer EJ, Giannini EH, Kuzmina N, et al.: Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis: results of the U.S.A.-U.S.S.R double-blind, placebo controlled trial. N Engl J Med 1986, 314:1269-1276.
21. Giannini EH, Brewer EJ, Kuzmina N, et al.: Auranofin in the treatment of juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo controlled cooperative trial. Arthritis Rheum 1990, 33:466-476.
22. Giannini EH, Brewer EJ, Kuzmina N, et al.: Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. N Engl J Med 1992, 326:1043-1049.
23. Lovell DJ, Giannini EH, Reiff A, et al.: Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000, 342:763-769.
24. Advisory Council of PRINTO: Bylaws of the Paediatric Rheumatology International Trials Organisation-PRINTO, edns 1 and 2. Available at www. printo.it.
25. Giannini EH, Ruperto N, Ravelli A, et al.: Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997, 40:1202-1209.
26. Ruperto N, Ravelli A, Falcini F, et al.: Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate. Ann Rheum Dis 1998, 57:38-41.
27. Albornoz MA: ACR formally adopts improvement criteria for juvenile arthritis (ACR Pediatric 30). ACR News 2002, 21:3.
28. Ruperto N, Murray KJ, Gerloni V, et al.: A randomized trial of parenteral methotrexate in intermediate versus higher doses in children with juvenile idiopathic arthritis who failed standard dose. Arthritis Rheum 2004, in press. This is the first PRINTO international trial with 595 patients enrolled from 20 countries that led to the establishment of the maximum dose and way of administration of MTX that should be administered to children with JIA. Of note, the trial has been conducted only with public funding from the European Union, with no pharmaceutical company support.
29. Ruperto N, Martini A, for the Paediatric Rheumatology International Trials Organization (PRINTO): Quality of life in juvenile idiopathic arthritis patients compared to healthy children. Clin Exp Rheumatol 2001, 19(suppl. 23):S1-S172.
30. Ruperto N, Ravelli A, Pistorio A, et al.: Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries. Review of the general methodology. Clin Exp Rheumatol 2001, 19:S1-S9.
31. Ruperto N, Ravelli A, Murray KJ, et al.: Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythe-matosus and juvenile dermatomyositis. Rheumatology (Oxford) 2003, 42:1452-1459. This is another pivotal work that led to the establishment of a standardized approach for the evaluation of response to therapy in JSLE and JDM.
32. Hirsch R: Pediatric rheumatology: a call to action. Curr Opin Rheumatol 2004, 15:571.
33. Connor JD: A look at the future of pediatric therapeutics: an investigator's perspective of the new pediatric rule. Pediatrics 1999, 104:610-613.
34. Food and Drug Administration: Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biologic products in pediatrics patients (21 CFR Parts 201, 312, 314, and 601). In Federal Register. 1998:63.
35. European Commission: Better Medicines for Children. Proposed Regulatory Actions on Paediatric Medicinal Products. Available at http://pharmacos. eudra.org/F2/pharmacos/docs/Doc2002/feb/cd_pediatrics_en.pdf.
36. European Commission: Commission Consultation on a Draft Proposal for a European Parliament and Council Regulation (EC) on Medicinal Products for Paediatric Use. Available at http://pharmacos.eudra.org/F2/pharmacos/docs/ Doc2004/mar/Paediatric%20consultation%20document%20 final%208%20March%2004.pdf.